Biodexa Revenue Per Share from 2010 to 2025

BDRX Stock   2.12  0.22  11.58%   
Biodexa Pharmaceticals Revenue Per Share yearly trend continues to be fairly stable with very little volatility. Revenue Per Share will likely drop to 13.18 in 2025. Revenue Per Share is the amount of revenue generated by Biodexa Pharmaceticals per share of stock, calculated by dividing total revenue by the average number of shares outstanding. View All Fundamentals
 
Revenue Per Share  
First Reported
2010-12-31
Previous Quarter
13.87
Current Value
13.18
Quarterly Volatility
129.83866855
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Biodexa Pharmaceticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biodexa Pharmaceticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 242 K, Selling General Administrative of 3.9 M or Other Operating Expenses of 11.7 M, as well as many indicators such as Price To Sales Ratio of 0.0119, Dividend Yield of 0.0 or PTB Ratio of 0.001. Biodexa financial statements analysis is a perfect complement when working with Biodexa Pharmaceticals Valuation or Volatility modules.
  
Check out the analysis of Biodexa Pharmaceticals Correlation against competitors.
For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

Latest Biodexa Pharmaceticals' Revenue Per Share Growth Pattern

Below is the plot of the Revenue Per Share of Biodexa Pharmaceticals over the last few years. It is the amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding. Biodexa Pharmaceticals' Revenue Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biodexa Pharmaceticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.43510 Years Trend
Slightly volatile
   Revenue Per Share   
       Timeline  

Biodexa Revenue Per Share Regression Statistics

Arithmetic Mean197.44
Geometric Mean121.41
Coefficient Of Variation65.76
Mean Deviation120.94
Median294.19
Standard Deviation129.84
Sample Variance16,858
Range282
R-Value(0.86)
Mean Square Error4,768
R-Squared0.74
Significance0.000021
Slope(23.40)
Total Sum of Squares252,871

Biodexa Revenue Per Share History

2025 13.18
2024 13.87
2023 12.06
2022 56.58
2021 57.41
2020 64.05

About Biodexa Pharmaceticals Financial Statements

Biodexa Pharmaceticals investors use historical fundamental indicators, such as Biodexa Pharmaceticals' Revenue Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biodexa Pharmaceticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Revenue Per Share 13.87  13.18 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.